DSM-Firmenich AG

DSFIR: XAMS (NLD)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|xDLOCK|&rmLOCK|TSFQXZ

DSM-Firmenich Earnings: Sales Growth Slows on Heightened Customer Caution; Shares Attractive

DSM-Firmenich reported a slowdown in third-quarter organic sales growth to 2% due to more cautious customer behavior. Full-year EBITDA guidance was lowered by EUR 100 million to EUR 2.3 billion, reflecting a larger currency headwind and a weaker-than-expected improvement in vitamins.

Sponsor Center